MX2020000185A - Formas polimorficas de dasatinib. - Google Patents

Formas polimorficas de dasatinib.

Info

Publication number
MX2020000185A
MX2020000185A MX2020000185A MX2020000185A MX2020000185A MX 2020000185 A MX2020000185 A MX 2020000185A MX 2020000185 A MX2020000185 A MX 2020000185A MX 2020000185 A MX2020000185 A MX 2020000185A MX 2020000185 A MX2020000185 A MX 2020000185A
Authority
MX
Mexico
Prior art keywords
dasatinib
present
butanediol
preparation
provides
Prior art date
Application number
MX2020000185A
Other languages
English (en)
Inventor
Venkata Raghavendracharyulu Palle
Mariappan Kaliappan
Ramakrishna Parameshwar Bhat
Jithendrababu Raghunadhachetty
Vijaybhaskar Reddy Regalla
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2020000185A publication Critical patent/MX2020000185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona el cocristal de dasatinib-timina y el cocristal de dasatinib-adenina. La presente invención proporciona además solvato de dasatinib-butanodiol. La presente invención proporciona además dasatinib (¿)-1,2- butanodiol cristalino, dasatinib (R)-l, 2-butanodiol cristalino, dasatinib (S)-1,2-butanodiol cristalino y dasatinib (:B-2,3 butanodiol cristalino y procesos para su preparación. La presente invención también proporciona un proceso para la preparación de dasatinib amorfo usando solvato de dasatinib-butanodiol. La presente invención proporciona además la preparación de dasatinib anhidro. La presente invención también proporciona un proceso para la preparación de dasatinib monohidrato a partir de dasatinib anhidro.
MX2020000185A 2017-07-07 2018-07-07 Formas polimorficas de dasatinib. MX2020000185A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201741024067 2017-07-07
IN201741029965 2017-08-24
IN201841001249 2018-01-11
IN201841007613 2018-02-28
PCT/IB2018/055022 WO2019008555A1 (en) 2017-07-07 2018-07-07 POLYMORPHIC FORMS OF DASATINIB

Publications (1)

Publication Number Publication Date
MX2020000185A true MX2020000185A (es) 2021-01-29

Family

ID=64949779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000185A MX2020000185A (es) 2017-07-07 2018-07-07 Formas polimorficas de dasatinib.

Country Status (12)

Country Link
US (1) US11059813B2 (es)
EP (1) EP3649126A4 (es)
JP (1) JP2020526528A (es)
KR (1) KR20200036867A (es)
CN (1) CN111108104A (es)
AU (1) AU2018297710A1 (es)
BR (1) BR112020000302A2 (es)
CA (1) CA3069107A1 (es)
MX (1) MX2020000185A (es)
RU (1) RU2020105723A (es)
SG (1) SG11202000098RA (es)
WO (1) WO2019008555A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2007035874A1 (en) 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
EP2537847A1 (en) 2007-10-23 2012-12-26 Teva Pharmaceutical Industries, Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CN102040596A (zh) * 2009-10-10 2011-05-04 上海希迪制药有限公司 达沙替尼多晶型物及其制备方法
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
CN102086195B (zh) * 2011-01-28 2013-04-03 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
US9340536B2 (en) * 2012-06-15 2016-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
CZ306598B6 (cs) * 2012-12-06 2017-03-22 Zentiva, K.S. Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu
WO2015049645A2 (en) * 2013-10-04 2015-04-09 Alembic Pharmaceuticals Limited An improved process for the preparation of dasatinib
EP3160963A1 (en) 2014-06-30 2017-05-03 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
EP3186284B1 (en) 2014-08-28 2022-04-06 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016178148A1 (en) * 2015-05-05 2016-11-10 Glenmark Pharmaceuticals Limited Process for preparation of dapagliflozin
WO2017002131A1 (en) 2015-06-29 2017-01-05 Msn Laboratories Private Limited Crystalline forms of n-(2-chloro-6-methy]phenvn-2-[f6-[4-(2-hvdroxvethvl)-l- piperazinvil-2-methvl-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof
US9845303B2 (en) * 2015-10-19 2017-12-19 Cadila Healthcare Limited Process for the preparation of dapagliflozin
WO2017098391A1 (en) * 2015-12-11 2017-06-15 Shilpa Medicare Limited Process for the preparation of dasatinib
WO2017134617A1 (en) 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Process for the preparation of amorphous dasatinib
BR112018015891A2 (pt) * 2016-02-03 2018-12-26 Dr Reddys Laboratories Ltd formas de estado sólido de dasatinib e processos para sua preparação

Also Published As

Publication number Publication date
WO2019008555A1 (en) 2019-01-10
KR20200036867A (ko) 2020-04-07
CA3069107A1 (en) 2019-01-10
US20200377495A1 (en) 2020-12-03
CN111108104A (zh) 2020-05-05
EP3649126A1 (en) 2020-05-13
JP2020526528A (ja) 2020-08-31
EP3649126A4 (en) 2021-04-07
BR112020000302A2 (pt) 2020-07-14
AU2018297710A2 (en) 2020-03-05
SG11202000098RA (en) 2020-02-27
AU2018297710A1 (en) 2020-02-27
US11059813B2 (en) 2021-07-13
RU2020105723A (ru) 2021-08-09

Similar Documents

Publication Publication Date Title
PH12020550246A1 (en) Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
PH12018501056A1 (en) High intensity sweeteners
WO2015132799A3 (en) Heterocyclic compounds
NZ747259A (en) Soluble c5ar antagonists
WO2017048702A8 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016011390A8 (en) Irak4 inhibiting agents
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2015145415A3 (en) Ibrutinib solid forms and production process therefor
NZ764150A (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
WO2017067530A3 (zh) 一种治疗***癌的组合、药物组合物及治疗方法
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MX2022015106A (es) Proceso para preparar tapinarof.
WO2016024286A3 (en) An improved process for synthesis of lenalidomide
TN2016000491A1 (en) Carboxamide derivatives.
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
WO2015111085A3 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
MY196804A (en) Class of bifunctional compounds with quaternary ammonium salt structure
MX2020000185A (es) Formas polimorficas de dasatinib.
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
WO2014195977A3 (en) Novel polymorphs of vismodegib